Co-Promotion Term Sample Clauses

The Co-Promotion Term clause defines the specific duration during which two or more parties collaborate to jointly promote a product or service. Typically, this clause outlines the start and end dates of the co-promotion period, and may include provisions for automatic renewal, early termination, or extension based on mutual agreement. Its core practical function is to establish clear expectations regarding the timeframe of the joint promotional efforts, thereby preventing misunderstandings and ensuring both parties are aligned on their commitments.
Co-Promotion Term. The Parties’ activities under this Agreement relating to the Co-Promotion Program in the United States shall commence on the date that Bayer gives Onyx notice of the anticipated commencement of Co-Promotion (at least [ * ] in advance of the anticipated First Commercial Sale of a Product in the United States) and shall remain in effect until the first to occur of the following (the “Co-Promotion Expiration Date”): (i) the date that Products are no longer sold in the United States due to a permanent Product withdrawal or recall, (ii) the mutual written agreement of both Parties to abandon the Co-Promotion Program in the United States, (iii) early termination of the Co-Promotion Program pursuant to Section 3.2 thereto (Change of Control) or Section 6.3 of the Agreement (for Material Breach), or (iv) termination of Onyx’s participation in the Co-Promotion Program, at Onyx’s option and in its discretion, upon not less than [ * ] prior written notice to Bayer (the “Co-Promotion Term”).
View Source
Co-Promotion Term. The Co-promotion Term shall begin on ----------------- the Effective Date and shall continue until [*]. (the "Co-promotion Term"); provided, that the Co-promotion Term is subject to earlier termination in -------- accordance with Section 15.2, 15.3, 15.4, or 15.5 below or by the Parties' mutual agreement.
View Source
Co-Promotion Term. Once executed by the Parties, the Co-Promotion Agreement shall remain in effect for as long as Teva is selling Licensed Product in the United States or Canada, unless earlier terminated pursuant to the terms of this Agreement or the Co-Promotion Agreement, provided that Teva shall have the right to terminate the Co-Promotion Agreement after [***] ([***]) years from the First Commercial Sale of a Licensed Product in the United States or Canada. OGX shall have the right to terminate the Co-Promotion Agreement at any time on not less than [***] written notice to Teva. OGX and Teva will cooperate in good faith throughout the term of the Co-Promotion Agreement to ensure that the exercise and performance of the Co-Promotion Activities and other co-promotion rights and obligations as described herein and in any Co-Promotion Agreement shall be exercised by OGX in accordance with the terms of the Co-Promotion Agreement.
View Source
Co-Promotion Term. Subject to Section 6.11(c), the Co-Promotion Right shall commence on the date specified in subsection (a) or (b) below, as applicable (the “Co-Promotion Commencement Date”) and shall continue in effect until the expiration or termination of this Agreement, unless terminated earlier as provided in this Article 6 (the “Co-Promotion Term”); provided that in no event shall Transcept commence activities under the Co-Promotion Right prior to the end of Sales Year 1; (a) If delivery of the written notice of the exercise of the Psychiatrist Co-Promotion Option by Transcept pursuant to Section 6.2 occurs on or prior to [***], [***] Confidential treatment has been requested for portions of this exhibit. These portions have been omitted from this exhibit and have been filed separately with the Securities and Exchange Commission. the Co-Promotion Right by Transcept will commence [***] (with the exact start date to be determined by Transcept in its sole discretion but in consultation with Purdue and specified in the initial notice made in the prior calendar year). For example, if Transcept delivers notice to Purdue on or before [***], such notice may specify that Transcept shall begin Promoting the Product to Psychiatrists [***] and [***]. (b) If delivery of the written notice of the exercise of the Psychiatrist Co-Promotion Option by Transcept pursuant to Section 6.2 occurs [***], such notice shall specify that Promotion by Transcept under the Co-Promotion Right will commence [***]. For example, if Transcept delivers notice to Purdue on [***], such notice shall specify that Transcept shall begin Promoting the Product to Psychiatrists on [***].
View Source
Co-Promotion Term. (a) The Parties’ co-promotion of the Licensed Products in the Asthma **** Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.
View Source

Related to Co-Promotion Term

  • Development Period The Contractor may commence pre-construction activities like utility shifting, boundary wall construction or any other activity assigned to the Contractor by the Authority to enable construction of the Project Highway immediately after signing of the Agreement, to the extent that such work is ready for execution. The Parties agree that these works may be taken up and completed to the extent feasible by the Contractor, before declaration of the Appointed Date, but no claim against the Authority for delay shall survive during this period and that the undertaking of these works by the Contractor shall not count towards the Scheduled Construction Period of the project which starts counting only from the Appointed Date. No construction activity of the Project Highway shall be undertaken during the development period.

  • Research Term The Research Program will be carried out during the two (2) year period following the Effective Date, unless this Agreement is terminated in accordance with Article 13 (such period, as may be extended pursuant to this Section 3.2, being the “Research Term”). BMS shall have the option to extend the Research Term for three (3) additional one (1) year periods on a year-by-year basis after the initial two (2) year period. At least one hundred eighty (180) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date) BMS will provide Ambrx with a nonbinding, good faith indication of whether or not BMS intends to extend the Research Term. In order to exercise its option to extend the Research Term, BMS must provide Ambrx a written notice exercising BMS’ option to extend the Research Term at least ninety (90) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date). If BMS does not provide such written notice, the Research Term will end when scheduled (i.e., on the applicable anniversary of the Effective Date). For each extension of the Research Term, subject to Section 3.4, the JRC will prepare an update to the Research Plan which will include an updated Budget for the BMS-funded Ambrx FTEs to perform the work required under such Research Plan and the projected Third Party Costs.

  • Joint Commercialization Committee Upon a decision by the JSC to activate the joint Commercialization committee, but in no case later than eighteen (18) months prior to the projected First Commercial Sale (the “Joint Commercialization Committee” or “JCC”), the Parties shall establish the JCC. The JCC shall hold its initial meeting within thirty (30) days of its establishment. Following its initial meeting, the JCC will meet in person, by teleconference or by video-teleconference at least [***] per [***] to review and discuss material decisions and key activities that relate to the matters set forth below. The JCC will be responsible for the communication, review and discussion of the Commercialization Plan and other Commercialization matters, including marketing strategy and planning, pricing, commercial manufacture, and [***], in each case in the Territory. Without limiting the foregoing, the JCC shall be responsible for: (a) reviewing and consulting with Coherus on the Commercialization Plan prior to adoption of the Commercialization Plan or changes by Licensee; (b) recommending the Commercialization Plan for approval by the JSC prior to adoption of the Commercialization Plan; (c) communicating with the JDC regarding the interrelationship between Development activities and potential Commercialization activities; (d) reviewing and monitoring the activities and progress against the Commercialization Plan; (e) monitoring and reporting on the competitive landscape for the Product in the Territory; (f) establishing appropriate processes for coordinating review of promotional materials for the Territory to ensure compliance with Applicable Laws and industry best practices; (g) overseeing the trademark and publication strategies for the Territory; and (h) communicating with the Parties regarding all of the foregoing.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Research Program The term “